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Background
The use of TLR ligands as mucosal adjuvant for vaccine
administration is already largely described; wherease the
use of NOD-like receptors ligands is still investigated.
As activation of intracytoplasmic NOD like-receptors is
able to induce production of pro-inflammatory mole-
cules, we have evaluated if their co-delivery into biode-
gradable nanocarriers carrying HIV-Gag antigens could
amplify the mucosal immune responses in mice at the
vaginal and intestinal (HIV replication site)
Methods
We used Poly(Lactic Acid) (PLA) nanoparticles (NPs)
(~200 nm) for co-delivery of p24 and NOD ligands. As
NOD like-receptors are mainly expressed by antigen
presenting cells, we first assessed the capacity of free or
encapsulated ligands to induce monocyte derived den-
dritic cells (MoDCs) maturation. Then, as NOD like-
receptors are principally expressed at the intestinal level
we compared by oral immunization of BALB/c mice
encapsulated ligands co-delivered with PLA-p24 NPs.
To assess the adjuvant effect, p24-specific cellular and
humoral responses were analyzed on splenocytes and in
vaginal washes, faeces and sera.
Results
The state of MoDCs maturation was characterized by
the expression of CD80, CD83 and CD86. We showed
that encapsulation of NOD1 or NOD2 ligand increases
significantly their expression, compared to the effect of
free ligands, probably due to a better uptake of encapsu-
lated ligands.
By analyzing humoral immune responses, we observed
that co-administration of p24 and NOD2 ligand by two
different NPs was the most efficient formulation to
induce anti-p24 IgG and IgA responses in faeces. By
contrast co-formulation of p24 and NOD1 ligand in the
same NP induced a better CD8 IFNg response.
Conclusion
Encapsulation of NOD ligands into PLA nanoparticles
seems to favour their action on DCs maturation, their
co-administration with PLA-p24 NPs inducing an adju-
vant effect. Use of those ligands as mucosal adjuvant
deserve further experiments and we are investigating the
mechanisms involved and increasing delivery efficacy
after co-encapsulations.
Author details
1IBCP-CNRS, Lyon, France. 2GIMAP, Saint Etienne, France. 3Cayla Invivogen,
Toulouse, France. 4University of Lyon - IMP, Lyon, France.
Published: 13 September 2012
doi:10.1186/1742-4690-9-S2-P194
Cite this article as: Pavot et al.: Induction of HIV mucosal immunity at
distal sites after encapsulation of NOD1 and NOD2 ligands in
biodegradable nanocarriers. Retrovirology 2012 9(Suppl 2):P194.
1IBCP-CNRS, Lyon, France
Full list of author information is available at the end of the article
Pavot et al. Retrovirology 2012, 9(Suppl 2):P194
http://www.retrovirology.com/content/9/S2/P194
© 2012 Pavot et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
